Sandbox:Mitra2: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
Line 8: | Line 8: | ||
! rowspan="2" |<small>Other Findings</small> | ! rowspan="2" |<small>Other Findings</small> | ||
|- style="background: #4479BA; color: #FFFFFF; text-align: center;" | |- style="background: #4479BA; color: #FFFFFF; text-align: center;" | ||
!<small> | !<small>Dyspnea on Exertion</small> | ||
!<small> | !<small>Chest Pain</small> | ||
!<small> | !<small>Hemoptysis</small> | ||
!<small> | !<small>Fever</small> | ||
!<small> | !<small>Tachypnea</small> | ||
!<small> | !<small>Tachycardia</small> | ||
!<small> | !<small>Chest X-ray</small> | ||
!<small> | !<small>ECG</small> | ||
!<small> | !<small>Echocardiography> | ||
!<small> | !<small>CT scan and CMRI</small> | ||
|- | |- | ||
|style="background: #DCDCDC; padding: 5px; text-align: center;" |[[COVID-19-associated heart failure|COVID-19-associated heart failure]] | |style="background: #DCDCDC; padding: 5px; text-align: center;" |[[COVID-19-associated heart failure|COVID-19-associated heart failure]] | ||
Line 42: | Line 42: | ||
| style="background: #F5F5F5; padding: 5px;" | Increased [[NT-proBNP]] and cardiac [[troponin]]s levels | | style="background: #F5F5F5; padding: 5px;" | Increased [[NT-proBNP]] and cardiac [[troponin]]s levels | ||
|- | |- | ||
|style="background: #DCDCDC; padding: 5px; text-align: center;" |[[COVID-associated pneumonia]] | |style="background: #DCDCDC; padding: 5px; text-align: center;" |[[COVID-19-associated pneumonia]] | ||
| style="background: #F5F5F5; padding: 5px;" |✔ (Usually high) | | style="background: #F5F5F5; padding: 5px;" |✔ (Usually high) | ||
| style="background: #F5F5F5; padding: 5px;" |✔ ([[Pleuritic]]) | | style="background: #F5F5F5; padding: 5px;" |✔ ([[Pleuritic]]) | ||
Line 50: | Line 50: | ||
| style="background: #F5F5F5; padding: 5px;" |✔ | | style="background: #F5F5F5; padding: 5px;" |✔ | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
*Consalidation | *[[Lobar Consalidation]] | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
*Prolonged PR interval | *Prolonged PR interval | ||
Line 56: | Line 56: | ||
| style="background: #F5F5F5; padding: 5px;" | - | | style="background: #F5F5F5; padding: 5px;" | - | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
*CT: Consalidation | *CT: [[Lobar Consalidation]] | ||
| style="background: #F5F5F5; padding: 5px;" | Increased inflammatory markers, including [[ESR]], [[hs-CRP]] | | style="background: #F5F5F5; padding: 5px;" | Increased inflammatory markers, including [[ESR]], [[hs-CRP]] | ||
|- | |- | ||
|style="background: #DCDCDC; padding: 5px; text-align: center;" |[[COVID-associated ARDS]] | |style="background: #DCDCDC; padding: 5px; text-align: center;" |[[COVID-19-associated ARDS]] | ||
| style="background: #F5F5F5; padding: 5px;" |✔ | | style="background: #F5F5F5; padding: 5px;" |✔ | ||
| style="background: #F5F5F5; padding: 5px;" |- | | style="background: #F5F5F5; padding: 5px;" |- | ||
Line 67: | Line 67: | ||
| style="background: #F5F5F5; padding: 5px;" |✔ | | style="background: #F5F5F5; padding: 5px;" |✔ | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
*Bilateral ground-glass opacities | *Bilateral [[ground-glass opacities]] | ||
| style="background: #F5F5F5; padding: 5px;" | - | | style="background: #F5F5F5; padding: 5px;" | - | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
*Signs of RV dysfunction/RV dilatation may be seen | *Signs of RV dysfunction/RV dilatation may be seen. | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
*CT: Bilateral | *CT: *Bilateral [[ground-glass opacities]] | ||
| style="background: #F5F5F5; padding: 5px;" | - | | style="background: #F5F5F5; padding: 5px;" | - | ||
|- | |- | ||
|style="background: #DCDCDC; padding: 5px; text-align: center;" |[[COVID-associated myocarditis]] | |style="background: #DCDCDC; padding: 5px; text-align: center;" |[[COVID-19-associated myocarditis]] | ||
| style="background: #F5F5F5; padding: 5px;" |✔ | | style="background: #F5F5F5; padding: 5px;" |✔ | ||
| style="background: #F5F5F5; padding: 5px;" |✔ | | style="background: #F5F5F5; padding: 5px;" |✔ | ||
Line 83: | Line 83: | ||
| style="background: #F5F5F5; padding: 5px;" |✔ | | style="background: #F5F5F5; padding: 5px;" |✔ | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
*Pericardial effusion may be detectable | *[[Pericardial effusion]] may be detectable | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
* Non-specific:may show nonspecific ST-T abnormalities, sinus tachycardia and conduction abnormalities (such as bundle-branch blocks or atrioventricular conduction delays) | * Non-specific:may show nonspecific ST-T abnormalities, [[sinus tachycardia]] and [[conduction abnormalities]] (such as bundle-branch blocks or atrioventricular conduction delays) | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
*Non-specific: In fulminant myocarditis cardiac chamber sizes are usually normal with an increased septal thickness (secondary to acute myocardial edema), whereas in acute myocarditis marked left ventricular dilation and normal wall thickness might be seen. | *Non-specific: In [[fulminant myocarditis]], cardiac chamber sizes are usually normal with an increased septal thickness (secondary to acute myocardial edema), whereas in acute [[myocarditis]] marked left ventricular dilation and normal wall thickness might be seen. | ||
*Pericardial effusion may be be seen. | *[[Pericardial effusion]] may be be seen. | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
*CMR: T2-weighted edema imaging shows the presence of “acute myocardial inflammation”. "Late gadolinium enhancement (LGE) imaging” can demonstrate myocardial damage. | *CMR: T2-weighted edema imaging shows the presence of “acute myocardial inflammation”. "[[Late gadolinium enhancement (LGE)]] imaging” can demonstrate myocardial damage. | ||
| style="background: #F5F5F5; padding: 5px;" | Increased cardiac [[troponin]]s level | | style="background: #F5F5F5; padding: 5px;" | Increased cardiac [[troponin]]s level | ||
|- | |- | ||
|style="background: #DCDCDC; padding: 5px; text-align: center;" |[[COVID-associated pulmonary embolism]] | |style="background: #DCDCDC; padding: 5px; text-align: center;" |[[COVID-19-associated pulmonary embolism]] | ||
| style="background: #F5F5F5; padding: 5px;" |✔ (Usually sudden-onset) | | style="background: #F5F5F5; padding: 5px;" |✔ (Usually sudden-onset) | ||
| style="background: #F5F5F5; padding: 5px;" |✔ (Pleauritic) | | style="background: #F5F5F5; padding: 5px;" |✔ ([[Pleauritic]]) | ||
| style="background: #F5F5F5; padding: 5px;" |✔ (If massive PE) | | style="background: #F5F5F5; padding: 5px;" |✔ (If massive PE) | ||
| style="background: #F5F5F5; padding: 5px;" |✔ (Low-grade) | | style="background: #F5F5F5; padding: 5px;" |✔ (Low-grade) | ||
Line 101: | Line 101: | ||
| style="background: #F5F5F5; padding: 5px;" |✔ | | style="background: #F5F5F5; padding: 5px;" |✔ | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
*May show Fleischner sign (enlarged pulmonary artery), [[Hampton hump]], [[Westermark's sign]] | *May show [[Fleischner sign]] (enlarged pulmonary artery), [[Hampton hump]], [[Westermark's sign]] | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
* Non-specific:may show S1Q3T3 pattern | * Non-specific:may show [[S1Q3T3]] pattern | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
*May show signs of RV strain, Rv dilatation, Rv dysfunction (if large PE) | *May show signs of RV strain, Rv dilatation, Rv dysfunction (if large PE) | ||
Line 112: | Line 112: | ||
*Polo-mint sign (partial filling defect surrounded by contrast) | *Polo-mint sign (partial filling defect surrounded by contrast) | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
*Increased D-dimer, fibrinogen, fibrin degradation products | *Increased [[D-dimer]], [[fibrinogen]], and [[fibrin degradation products]] levels | ||
*May have symptoms and/or signs of accompanying DVT | *May have symptoms and/or signs of accompanying [[DVT]] |
Revision as of 16:54, 20 July 2020
Diseases | Symptoms | Physical Examination | Diagnostic tests | Other Findings | |||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Dyspnea on Exertion | Chest Pain | Hemoptysis | Fever | Tachypnea | Tachycardia | Chest X-ray | ECG | Echocardiography> | CT scan and CMRI | ||
COVID-19-associated heart failure | ✔ | - | ✔ | - | ✔ | ✔ |
|
|
|
|
Increased NT-proBNP and cardiac troponins levels |
COVID-19-associated pneumonia | ✔ (Usually high) | ✔ (Pleuritic) | ✔ | ✔ | ✔ | ✔ |
|
- | Increased inflammatory markers, including ESR, hs-CRP | ||
COVID-19-associated ARDS | ✔ | - | ✔ | ✔ | ✔ | ✔ |
|
- |
|
|
- |
COVID-19-associated myocarditis | ✔ | ✔ | - | ✔ | ✔ | ✔ |
|
|
|
|
Increased cardiac troponins level |
COVID-19-associated pulmonary embolism | ✔ (Usually sudden-onset) | ✔ (Pleauritic) | ✔ (If massive PE) | ✔ (Low-grade) | ✔ | ✔ |
|
|
|
|
|